Women with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy face a higher risk for severe adverse outcomes to their fetus or newborn, new research indicates.
Roivant Sciences said on Monday its experimental drug to treat systemic lupus erythematosus failed to reduce symptoms of the autoimmune disease in a mid-stage study.
The revised indication is based on recent findings from a prespecified interim analysis showing little benefit in patients whose tumors do not express PD-L1.
Trastuzumab deruxtecan (T-DXd) provided sustained clinically meaningful improvement versus physician’s choice of treatment (TPC) for patients with advanced breast cancer and low HER2 expression.